Vol 9, No 1 (2018)
Review paper
Published online: 2018-05-23

open access

Page views 791
Article views/downloads 2053
Get Citation

Connect on Social Media

Connect on Social Media

The role of viral infection induced alloreactivity in patients with allogeneic hematopoietic stem cell transplantations

Mateusz Maciej Sowiński1, Alicja Bukowska1
Hematologia 2018;9(1):15-21.

Abstract

Viral infection activated alloreactive peripheral memory T-cells present in the host are considered as one of the causes of transplant related complications during post-transplant period of unrelated donor and haploidentical graft transplantation procedures. Antibody and T-cell receptor coding genes homology and their analogous rearrangement process help to understand cellular and humoral alloreactivity, mediated by alloreactive memory T-cells and antibodies, respectively. Simple tests using single antigen presenting cells or human leukocyte antigen (HLA)-mismatched recipient peripheral blood mononuclear cells vs. virus specific donor T-cells and more sophisticated natural killer cells degranulation marker assays based on flow cytometry enable to rule out or confirm alloreactivity thus increasing the chance of appropriate post-transplant treatment path selection.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Yoshihara S, Taniguchi K, Ogawa H, et al. The role of HLA antibodies in allogeneic SCT: is the 'type-and-screen' strategy necessary not only for blood type but also for HLA? Bone Marrow Transplant. 2012; 47(12): 1499–1506.
  2. Kolasiński M. Udział pracowni typowania tkankowego w procedurze alokacji nerek pobranych od dawców zmarłych. In: Bogunia-Kubik K. ed. Badania immunogenetyczne w transplantologii i diagnostyce, praca zbiorowa. I-BIS S.C, Wrocław 2012: 58–65.
  3. Yin Y, Mariuzza RA. The multiple mechanisms of T cell receptor cross-reactivity. Immunity. 2009; 31(6): 849–851.
  4. Selin LK, Brehm MA. Frontiers in nephrology: heterologous immunity, T cell cross-reactivity, and alloreactivity. J Am Soc Nephrol. 2007; 18(8): 2268–2277.
  5. Geneugelijk K, Thus KA, Spierings E. Predicting alloreactivity in transplantation. J Immunol Res. 2014; 2014: 159479.
  6. Ayala García MA, González Yebra B, López Flores AL, et al. The major histocompatibility complex in transplantation. J Transplant. 2012; 2012: 842141.
  7. Gołąb J, Jakóbisiak M, Lasek W, Stokłosa T. Immunologia. PWN, Warszawa 2012.
  8. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002; 8(6): 582–587.
  9. Ślebioda, TJ, Kaszubowska L, Kmieć Z. Nowe mechanizmy aktywacji komórek NK w przebiegu infekcji wirusowych. Postępy Biologii Komórki. 2012; 39: 61–83.
  10. Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, et al. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol. 2010; 135(1): 1–11.
  11. Vukmanovic S, Petroff M, Stevens A, et al. Alloreactivity-Based Medical Conditions. Clin Dev Immunol. 2013; 2013: 1–2.
  12. Burrows SR, Khanna R, Burrows JM, et al. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med. 1994; 179(4): 1155–1161.
  13. De Santis D, Foley BA, John E, et al. Rapid, flow cytometric assay for NK alloreactivity reveals exceptions to rules governing alloreactivity. Biol Blood Marrow Transplant. 2010; 16(2): 179–191.
  14. Bharadwaj M, Mifsud NA, McCluskey J. Detection and characterisation of alloreactive T cells. Methods Mol Biol. 2012; 882: 309–337.
  15. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295(5562): 2097–2100.
  16. Moretta A, Pende D, Locatelli F, et al. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clin Exp Immunol. 2009; 157(3): 325–331.
  17. Foley BA, De Santis D, Van Beelen E, et al. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood. 2008; 112(2): 435–443.
  18. Winter CC, Gumperz JE, Parham P, et al. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol. 1998; 161(2): 571–577.
  19. Moesta AK, Norman PJ, Yawata M, et al. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol. 2008; 180(6): 3969–3979.
  20. Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009; 113(13): 3119–3129.
  21. Janeway CA, Travers J, Walport M, Shlomchik MJ. T-cell receptor gene rearrangement. In: The Immune System in Health and Disease. 5th edition. Garland Publishing, New York 2001.
  22. Cornberg M, Chen AT, Wilkinson LA, et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest. 2006; 116(5): 1443–1456.
  23. Brehm M, Pinto A, Daniels K, et al. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol. 2002; 3(7): 627–634.
  24. Amir AL, D'Orsogna L, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood. 2010; 115(15): 3146–3157.
  25. Sprent J, Surh CD. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol. 2011; 12(6): 478–484.
  26. D'Orsogna LJA, Roelen DL, Doxiadis IIN, et al. Alloreactivity from human viral specific memory T-cells. Transpl Immunol. 2010; 23(4): 149–155.
  27. D'Orsogna LJA, Roelen DL, Doxiadis IIN, et al. Screening of viral specific T-cell lines for HLA alloreactivity prior to adoptive immunotherapy may prevent GvHD. Transpl Immunol. 2011; 24(3): 141.
  28. D'Orsogna LJ, Amir AL, Zoet YM, et al. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire. Tissue Antigens. 2009; 74(4): 290–297.



Hematology in Clinical Practice